PIK3CA and neoplasm: In contrast, in SHR-negative larger tumours (≥ 2 cm), patients with PIK3CA- mutations (n = 14) showed a trend to better 5 years-RFI probability (85.7%) compared to those with wildtype PIK3CA (5 years RFI 66.1%, HR 2.75; 95% CI 0.657–11.527).